Advances in the systemic therapy for recurrent meningiomas and the challenges ahead

References

• WHO Classification of CNS tumors. Editorial Board. World Health Organization Classification of Tumours of the Central Nervous System. 5th ed. Lyon, FR: International Agency for Research on Cancer; 2022.
   Google Scholar
• Vernooij MW, Ikram MA, Tanghe HL, et al. Incidental findings on brain MRI in the general population. N Engl J Med. 2007 Nov 1;357(18):1821–1828. doi: 10.1056/NEJMoa070972
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014 Oct;16(Suppl 4):iv1–63. doi: 10.1093/neuonc/nou223
   PubMed Web of Science ®Google Scholar
• Lukas RV, Mrugala MM. Nonmalignant brain tumors. Continuum (MinneapMinn). 2020 Dec;26(6):1495–1522. doi: 10.1212/CON.0000000000000942
   PubMedGoogle Scholar
• Mathews JD, Forsythe AV, Brady Z, et al. Cancer risk in 680,000 people exposed to computed tomography scans in childhood or adolescence: data linkage study of 11 million Australians. BMJ. 2013 May 21;346:f2360. doi: 10.1136/bmj.f2360
   PubMedGoogle Scholar
• Pearce MS, Salotti JA, Little MP, et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet. 2012 Aug 4;380(9840):499–505. doi: 10.1016/S0140-6736(12)60815-0
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Adel Fahmideh M, Cote DJ, et al. Risk factors for childhood and adult primary brain tumors. Neuro Oncol. 2019 Nov 4;21(11):1357–1375. doi: 10.1093/neuonc/noz123
   PubMed Web of Science ®Google Scholar
• Claus EB, Calvocoressi L, Bondy ML, et al. Exogenous hormone use, reproductive factors, and risk of intracranial meningioma in females. J Neurosurg. 2013 Mar;118(3):649–656. doi: 10.3171/2012.9.JNS12811
   PubMed Web of Science ®Google Scholar
• Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. J Neurooncol. 2010 Sep;99(3):307–314. doi: 10.1007/s11060-010-0386-3
   PubMed Web of Science ®Google Scholar
• Asgharian B, Chen YJ, Patronas NJ, et al. Meningiomas may be a component tumor of multiple endocrine neoplasia type 1. Clin Cancer Res. 2004 Feb 1;10(3):869–880. doi: 10.1158/1078-0432.CCR-0938-3
   PubMed Web of Science ®Google Scholar
• Coy S, Rashid R, Stemmer-Rachamimov A, et al. An update on the CNS manifestations of neurofibromatosis type 2. Acta Neuropathol. 2020 Apr;139(4):643–665. doi: 10.1007/s00401-019-02029-5
   PubMed Web of Science ®Google Scholar
• Aavikko M, Li SP, Saarinen S, et al. Loss of SUFU function in familial multiple meningioma. Am J Hum Genet. 2012 Sep 7;91(3):520–526. doi: 10.1016/j.ajhg.2012.07.015
   PubMed Web of Science ®Google Scholar
• Askaner G, Lei U, Bertelsen B, et al. Novel SUFU frameshift variant leading to meningioma in three generations in a family with Gorlin syndrome. Case Rep Genet. 2019;2019:9650184. doi: 10.1155/2019/9650184
   PubMedGoogle Scholar
• Evans DG, Oudit D, Smith MJ, et al. First evidence of genotype-phenotype correlations in Gorlin syndrome. J Med Genet. 2017 Aug;54(8):530–536. doi: 10.1136/jmedgenet-2017-104669
   PubMed Web of Science ®Google Scholar
• Kijima C, Miyashita T, Suzuki M, et al. Two cases of nevoid basal cell carcinoma syndrome associated with meningioma caused by a PTCH1 or SUFU germline mutation. Fam Cancer. 2012 Dec;11(4):565–570. doi: 10.1007/s10689-012-9548-0
   PubMed Web of Science ®Google Scholar
• Kerr K, Qualmann K, Esquenazi Y, et al. Familial syndromes involving meningiomas provide mechanistic insight into sporadic disease. Neurosurgery. 2018 Dec 1;83(6):1107–1118. doi: 10.1093/neuros/nyy121
   PubMed Web of Science ®Google Scholar
• Smith MJ, O’Sullivan J, Bhaskar SS, et al. Loss-of-function mutations in SMARCE1 cause an inherited disorder of multiple spinal meningiomas. Nat Genet. 2013 Mar;45(3):295–298. doi: 10.1038/ng.2552
   PubMed Web of Science ®Google Scholar
• Verstegen MJ, van den Munckhof P, Troost D, et al. Multiple meningiomas in a patient with Rubinstein-Taybi syndrome. Case Report J Neurosurg. 2005 Jan;102(1):167–168. doi: 10.3171/jns.2005.102.1.0167
   PubMed Web of Science ®Google Scholar
• Williams EA, Santagata S, Wakimoto H, et al. Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic. Acta Neuropathol Commun. 2020 Oct 21;8(1):171. doi: 10.1186/s40478-020-01040-2
   PubMed Web of Science ®Google Scholar
• Low JT, Ostrom QT, Cioffi G, et al. Primary brain and other central nervous system tumors in the United States (2014-2018): a summary of the CBTRUS statistical report for clinicians. Neurooncol Pract. 2022 May;9(3):165–182. doi: 10.1093/nop/npac015
   PubMed Web of Science ®Google Scholar
• Drappatz J. How useful is chemotherapy for atypical and anaplastic meningiomas? Expert Opin Pharmacother. 2022 Oct;23(14):1559–1561. doi: 10.1080/14656566.2022.2131394
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Wesseling P, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231–1251. doi: 10.1093/neuonc/noab106
   PubMed Web of Science ®Google Scholar
• Behling F, Fodi C, Gepfner-Tuma I, et al. H3K27me3 loss indicates an increased risk of recurrence in the Tubingen meningioma cohort. Neuro Oncol. 2021 Aug 2;23(8):1273–1281. doi: 10.1093/neuonc/noaa303
   PubMed Web of Science ®Google Scholar
• Nassiri F, Wang JZ, Singh O, et al. Loss of H3K27me3 in meningiomas. Neuro Oncol. 2021 Aug 2;23(8):1282–1291. doi: 10.1093/neuonc/noab036
   PubMed Web of Science ®Google Scholar
• Katz LM, Hielscher T, Liechty B, et al. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. Acta Neuropathol. 2018 Jun;135(6):955–963. doi: 10.1007/s00401-018-1844-9
   PubMed Web of Science ®Google Scholar
• Marciscano AE, Stemmer-Rachamimov AO, Niemierko A, et al. Benign meningiomas (WHO grade I) with atypical histological features: correlation of histopathological features with clinical outcomes. J Neurosurg. 2016 Jan;124(1):106–114. doi: 10.3171/2015.1.JNS142228
   PubMed Web of Science ®Google Scholar
• Rogers L, Barani I, Chamberlain M, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. A RANO review. J Neurosurg. 2015 Jan;122(1):4–23. doi: 10.3171/2014.7.JNS131644
   PubMed Web of Science ®Google Scholar
• Chukwueke UN, Wen PY. Medical management of meningiomas. Handb Clin Neurol. 2020;170:291–302.
   PubMedGoogle Scholar
• Buerki RA, Horbinski CM, Kruser T, et al. An overview of meningiomas. Future Oncol. 2018 Sep;14(21):2161–2177. doi: 10.2217/fon-2018-0006
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Galanis E, Butowski N, et al. Advances in multidisciplinary therapy for meningiomas. Neuro Oncol. 2019 Jan 14;21(Suppl 1):i18–i31. doi: 10.1093/neuonc/noy136
   PubMedGoogle Scholar
• Kaur G, Sayegh ET, Larson A, et al. Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. Neuro Oncol. 2014 May;16(5):628–636. doi: 10.1093/neuonc/nou025
   PubMed Web of Science ®Google Scholar
• Simpson D. The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957 Feb;20(1):22–39. doi: 10.1136/jnnp.20.1.22
   PubMed Web of Science ®Google Scholar
• Goldbrunner R, Stavrinou P, Jenkinson MD, et al. EANO guideline on the diagnosis and management of meningiomas. Neuro Oncol. 2021 Nov 2;23(11):1821–1834. doi: 10.1093/neuonc/noab150
   PubMed Web of Science ®Google Scholar
• Huang RY, Bi WL, Weller M, et al. Proposed response assessment and endpoints for meningioma clinical trials: report from the response assessment in neuro-oncology working group. Neuro Oncol. 2019 Jan 1;21(1):26–36. doi: 10.1093/neuonc/noy137
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Wen PY. Advances in meningioma therapy. Curr Neurol Neurosci Rep. 2009 May;9(3):231–240. doi: 10.1007/s11910-009-0034-5
   PubMed Web of Science ®Google Scholar
• Horbinski C, Nabors LB, Portnow J, et al. NCCN guidelines(R) insights: central nervous system cancers, version 2.2022. J Natl Compr Canc Netw. 2023 Jan;21(1):12–20. doi: 10.6004/jnccn.2023.0002
   PubMedGoogle Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Temozolomide for treatment-resistant recurrent meningioma. Neurology. 2004 Apr 13;62(7):1210–1212. doi: 10.1212/01.WNL.0000118300.82017.F4
   PubMedGoogle Scholar
• Chamberlain MC. Adjuvant combined modality therapy for malignant meningiomas. J Neurosurg. 1996 May;84(5):733–736. doi: 10.3171/jns.1996.84.5.0733
   PubMed Web of Science ®Google Scholar
• Shah D, Menon NS, Puranik A, et al. Efficacy of gemcitabine in recurrent meningioma: a phase II study. J Clin Oncol. 2022;40(16_suppl):e14044–e14044. doi: 10.1200/JCO.2022.40.16_suppl.e14044
   Web of Science ®Google Scholar
• Wen PY, Quant E, Drappatz J, et al. Medical therapies for meningiomas. J Neurooncol. 2010 Sep;99(3):365–378. doi: 10.1007/s11060-010-0349-8
   PubMed Web of Science ®Google Scholar
• Preusser M, Silvani A, Le Rhun E, et al. Trabectedin for recurrent WHO grade 2 or 3 meningioma: a randomized phase II study of the EORTC brain tumor group (EORTC-1320-BTG). Neuro Oncol. 2022 May 4;24(5):755–767. doi: 10.1093/neuonc/noab243
   PubMed Web of Science ®Google Scholar
• Preusser M, Spiegl-Kreinecker S, Lötsch D, et al. Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer. 2012 Oct 15;118(20):5038–5049. doi: 10.1002/cncr.27460
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Tsao-Wei DD, Groshen S. Salvage chemotherapy with CPT-11 for recurrent meningioma. J Neurooncol. 2006 Jul;78(3):271–276. doi: 10.1007/s11060-005-9093-x
   PubMed Web of Science ®Google Scholar
• Gupta V, Su YS, Samuelson CG, et al. Irinotecan: a potential new chemotherapeutic agent for atypical or malignant meningiomas. J Neurosurg. 2007 Mar;106(3):455–462. doi: 10.3171/jns.2007.106.3.455
   PubMed Web of Science ®Google Scholar
• Swinnen LJ, Rankin C, Rushing EJ, et al. Phase II study of hydroxyurea for unresectable meningioma (Southwest Oncology group S9811). J Clin Oncol. 2009;27(15_suppl):2063–2063. doi: 10.1200/jco.2009.27.15_suppl.2063
   Web of Science ®Google Scholar
• Grunberg SM, Weiss MH. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J Neurooncol. 1990 Feb;8(1):61–65. doi: 10.1007/BF00182088
   PubMed Web of Science ®Google Scholar
• Jääskeläinen J, Laasonen E, Kärkkäinen J, et al. Hormone treatment of meningiomas: lack of response to medroxyprogesterone acetate (MPA). A pilot study of five cases. Acta Neurochir (Wien). 1986;80(1–2):35–41. doi: 10.1007/BF01809555
   PubMed Web of Science ®Google Scholar
• Grunberg SM, Weiss MH, Russell CA, et al. Long-term administration of mifepristone (RU486): clinical tolerance during extended treatment of meningioma. Cancer Invest. 2006 Dec;24(8):727–733. doi: 10.1080/07357900601062339
   PubMed Web of Science ®Google Scholar
• Markwalder TM, Seiler RW, Zava DT. Antiestrogenic therapy of meningiomas–a pilot study. Surg Neurol. 1985 Sep;24(3):245–249. doi: 10.1016/0090-3019(85)90030-8
   PubMedGoogle Scholar
• Goodwin JW, Crowley J, Eyre HJ, et al. A phase II evaluation of tamoxifen in unresectable or refractory meningiomas: a southwest oncology group study. J Neurooncol. 1993 Jan;15(1):75–77. doi: 10.1007/BF01050266
   PubMed Web of Science ®Google Scholar
• Ji J, Sundquist J, Sundquist K. Association of tamoxifen with meningioma: a population-based study in Sweden. Eur J Cancer Prev. 2016 Jan;25(1):29–33. doi: 10.1097/CEJ.0000000000000133
   PubMed Web of Science ®Google Scholar
• Norden AD, Drappatz J, Wen PY. Targeted drug therapy for meningiomas. Neurosurg Focus. 2007;23(4):E12. doi: 10.3171/FOC-07/10/E12
   PubMedGoogle Scholar
• Boetto J, Peyre M, Kalamarides M. Mouse models in meningioma research: a systematic review. Cancers (Basel). 2021 Jul 26;13(15):3712. doi: 10.3390/cancers13153712
   PubMed Web of Science ®Google Scholar
• Boetto J, Peyre M, Kalamarides M. Meningiomas from a developmental perspective: exploring the crossroads between meningeal embryology and tumorigenesis. Acta Neurochir (Wien). 2021 Jan;163(1):57–66. doi: 10.1007/s00701-020-04650-w
   PubMed Web of Science ®Google Scholar
• Gupta S, Bi WL, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018 Apr;44(4):E3. doi: 10.3171/2018.1.FOCUS17754
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ, Fadul CE. Recurrent meningioma: salvage therapy with long-acting somatostatin analogue. Neurology. 2007 Sep 4;69(10):969–973. doi: 10.1212/01.wnl.0000271382.62776.b7
   PubMed Web of Science ®Google Scholar
• Simó M, Argyriou AA, Macià M, et al. Recurrent high-grade meningioma: a phase II trial with somatostatin analogue therapy. Cancer Chemother Pharmacol. 2014 May;73(5):919–923. doi: 10.1007/s00280-014-2422-z
   PubMed Web of Science ®Google Scholar
• Reardon DA, Norden AD, Desjardins A, et al. Phase II study of Gleevec® plus hydroxyurea (HU) in adults with progressive or recurrent meningioma. J Neurooncol. 2012 Jan;106(2):409–415. doi: 10.1007/s11060-011-0687-1
   PubMed Web of Science ®Google Scholar
• Graillon T, Romano D, Defilles C, et al. Octreotide therapy in meningiomas: in vitro study, clinical correlation, and literature review. J Neurosurg. 2017 Sep;127(3):660–669. doi: 10.3171/2016.8.JNS16995
   PubMed Web of Science ®Google Scholar
• Norden AD, Ligon KL, Hammond SN, et al. Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20;84(3):280–286. doi: 10.1212/WNL.0000000000001153
   PubMed Web of Science ®Google Scholar
• Schulz C, Mathieu R, Kunz U, et al. Treatment of unresectable skull base meningiomas with somatostatin analogs. Neurosurg Focus. 2011 May;30(5):E11. doi: 10.3171/2011.1.FOCUS111
   PubMed Web of Science ®Google Scholar
• Hrachova M, Nguyen ENT, Fu BD, et al. A retrospective interventional cohort study to assess the safety and efficacy of sandostatin LAR for treatment of recurrent and/or refractory meningiomas. Front Neurol. 2020;11:373. doi: 10.3389/fneur.2020.00373
   PubMed Web of Science ®Google Scholar
• Mirian C, Duun-Henriksen AK, Maier A, et al. Somatostatin receptor-targeted radiopeptide therapy in treatment-refractory meningioma: Individual patient data meta-analysis. J Nucl Med. 2021 Apr;62(4):507–513. doi: 10.2967/jnumed.120.249607
   PubMed Web of Science ®Google Scholar
• Bailey DL, Willowson KP, Harris M, et al. (64)Cu treatment Planning and (67)Cu therapy with Radiolabeled [(64)Cu/(67)Cu]MeCOSar-octreotate in subjects with unresectable multifocal meningioma: initial results for human imaging, safety, biodistribution, and radiation dosimetry. J Nucl Med. 2023 May;64(5):704–710. doi: 10.2967/jnumed.122.264586
   PubMed Web of Science ®Google Scholar
• Peyre M, Salaud C, Clermont-Taranchon E, et al. PDGF activation in PGDS-positive arachnoid cells induces meningioma formation in mice promoting tumor progression in combination with Nf2 and Cdkn2ab loss. Oncotarget. 2015 Oct 20;6(32):32713–32722. doi: 10.18632/oncotarget.5296
   PubMedGoogle Scholar
• Todo T, Adams EF, Fahlbusch R, et al. Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor. J Neurosurg. 1996 May;84(5):852–858. discussion 858-9. doi: 10.3171/jns.1996.84.5.0852
   PubMed Web of Science ®Google Scholar
• Yang SY, Xu GM. Expression of PDGF and its receptor as well as their relationship to proliferating activity and apoptosis of meningiomas in human meningiomas. J Clin Neurosci. 2001 May;8(1):49–53. doi: 10.1054/jocn.2001.0877
   PubMedGoogle Scholar
• Wen PY, Yung WK, Lamborn KR, et al. Phase II study of imatinib mesylate for recurrent meningiomas (North American brain tumor consortium study 01-08). Neuro Oncol. 2009 Dec;11(6):853–860. doi: 10.1215/15228517-2009-010
   PubMed Web of Science ®Google Scholar
• Mazza E, Brandes A, Zanon S, et al. Hydroxyurea with or without imatinib in the treatment of recurrent or progressive meningiomas: a randomized phase II trial by Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2016 Jan;77(1):115–120. doi: 10.1007/s00280-015-2927-0
   PubMed Web of Science ®Google Scholar
• Goldman CK, Bharara S, Palmer CA, et al. Brain edema in meningiomas is associated with increased vascular endothelial growth factor expression. Neurosurgery. 1997 Jun;40(6):1269–1277. doi: 10.1097/00006123-199706000-00029
   PubMed Web of Science ®Google Scholar
• Lee SH, Lee YS, Hong YG, et al. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas. APMIS. 2014 Jan;122(1):16–24. doi: 10.1111/apm.12079
   PubMed Web of Science ®Google Scholar
• Lou E, Sumrall AL, Turner S, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012 Aug;109(1):63–70. doi: 10.1007/s11060-012-0861-0
   PubMed Web of Science ®Google Scholar
• Nayak L, Iwamoto FM, Rudnick JD, et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol. 2012 Aug;109(1):187–193. doi: 10.1007/s11060-012-0886-4
   PubMed Web of Science ®Google Scholar
• Kumthekar P, Grimm SA, Aleman RT, et al. A multi-institutional phase II trial of bevacizumab for recurrent and refractory meningioma. Neurooncol Adv. 2022 Jan;4(1):vdac123. doi: 10.1093/noajnl/vdac123
   PubMedGoogle Scholar
• Graillon T, Tabouret E, Chinot O. Chemotherapy and targeted therapies for meningiomas: what is the evidence? Curr Opin Neurol. 2021 Dec 1;34(6):857–867. doi: 10.1097/WCO.0000000000001002
   PubMed Web of Science ®Google Scholar
• Kaley TJ, Wen P, Schiff D, et al. Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan;17(1):116–121. doi: 10.1093/neuonc/nou148
   PubMed Web of Science ®Google Scholar
• Raheja A, Colman H, Palmer CA, et al. Dramatic radiographic response resulting in cerebrospinal fluid rhinorrhea associated with sunitinib therapy in recurrent atypical meningioma: case report. J Neurosurg. 2017 Nov;127(5):965–970. doi: 10.3171/2016.9.JNS161629
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Grimm SA, Rademaker A, et al. A phase II trial of PTK787/ZK 222584 in recurrent or progressive radiation and surgery refractory meningiomas. J Neurooncol. 2014 Mar;117(1):93–101. doi: 10.1007/s11060-014-1358-9
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Borgman-Hagey AE, Kelley RK. Cabozantinib in hepatocellular carcinoma. N Engl J Med. 2018 Oct 4;379(14):1384–1385. doi: 10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Meyer T, Cheng AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 2018 Jul 5;379(1):54–63. doi: 10.1056/NEJMoa1717002
   PubMed Web of Science ®Google Scholar
• Hilton DA, Shivane A, Kirk L, et al. Activation of multiple growth factor signalling pathways is frequent in meningiomas. Neuropathology. 2016 Jun;36(3):250–261. doi: 10.1111/neup.12266
   PubMed Web of Science ®Google Scholar
• Yun S, Koh JM, Lee KS, et al. Expression of c-MET in Invasive meningioma. J Pathol Transl Med. 2015 Jan;49(1):44–51. doi: 10.4132/jptm.2014.10.13
   PubMedGoogle Scholar
• Norden AD, Raizer JJ, Abrey LE, et al. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010 Jan;96(2):211–217. doi: 10.1007/s11060-009-9948-7
   PubMed Web of Science ®Google Scholar
• Shahbandi A, Shah DS, Hadley CC, et al. The role of Pharmacotherapy in treatment of meningioma: a systematic review. Cancers (Basel). 2023 Jan 12;15(2):483. doi: 10.3390/cancers15020483
   PubMed Web of Science ®Google Scholar
• Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012 Jun 7;366(23):2171–2179. doi: 10.1056/NEJMoa1113713
   PubMed Web of Science ®Google Scholar
• Chari NS, McDonnell TJ. The sonic hedgehog signaling network in development and neoplasia. Adv Anat Pathol. 2007 Sep;14(5):344–352. doi: 10.1097/PAP.0b013e3180ca8a1d
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Horowitz PM, Santagata S, et al. Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet. 2013 Mar;45(3):285–289. doi: 10.1038/ng.2526
   PubMed Web of Science ®Google Scholar
• Mei Y, Bi WL, Greenwald NF, et al. Genomic profile of human meningioma cell lines. PLoS One. 2017;12(5):e0178322. doi: 10.1371/journal.pone.0178322
   PubMed Web of Science ®Google Scholar
• Graillon T, Sanson M, Campello C, et al. Everolimus and octreotide for patients with recurrent meningioma: results from the phase II CEVOREM trial. Clin Cancer Res. 2020 Feb 1;26(3):552–557. doi: 10.1158/1078-0432.CCR-19-2109
   PubMed Web of Science ®Google Scholar
• Shih KC, Chowdhary S, Rosenblatt P, et al. A phase II trial of bevacizumab and everolimus as treatment for patients with refractory, progressive intracranial meningioma. J Neurooncol. 2016 Sep;129(2):281–288. doi: 10.1007/s11060-016-2172-3
   PubMed Web of Science ®Google Scholar
• Weller M, Roth P, Sahm F, et al. Durable control of metastatic AKT1-mutant WHO grade 1 meningothelial meningioma by the AKT inhibitor, AZD5363. J Natl Cancer Inst. 2017 Mar 1;109(3):1–4. doi: 10.1093/jnci/djw320
   PubMedGoogle Scholar
• Brastianos PK, Twohy EL, Gerstner ER, et al. Alliance A071401: Phase II trial of focal adhesion kinase inhibition in meningiomas with somatic NF2 mutations. J Clin Oncol. 2023 Jan 20;41(3):618–628. doi: 10.1200/JCO.21.02371
   PubMed Web of Science ®Google Scholar
• Dolcet X, Llobet D, Pallares J, et al. NF-kB in development and progression of human cancer. Virchows Arch. 2005 May;446(5):475–482. doi: 10.1007/s00428-005-1264-9
   PubMed Web of Science ®Google Scholar
• Carneiro BA, Cavalcante L, Bastos BR, et al. Phase I study of 9-ing-41, a small molecule selective glycogen synthase kinase-3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory tumors. J Clin Oncol. 2020;38(15_suppl):3507–3507. doi: 10.1200/JCO.2020.38.15_suppl.3507
   Web of Science ®Google Scholar
• Shankar GM, Santagata S. BAP1 mutations in high-grade meningioma: implications for patient care. Neuro Oncol. 2017 Oct 19;19(11):1447–1456. doi: 10.1093/neuonc/nox094
   PubMed Web of Science ®Google Scholar
• Shankar GM, Abedalthagafi M, Vaubel RA, et al. Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. Neuro Oncol. 2017 Apr 1;19(4):535–545. doi: 10.1093/neuonc/nox094
   PubMed Web of Science ®Google Scholar
• Harmanci AS, Youngblood MW, Clark VE, et al. Integrated genomic analyses of de novo pathways underlying atypical meningiomas. Nat Commun. 2017 Feb 14;8(1):14433. doi: 10.1038/ncomms14433
   PubMedGoogle Scholar
• Zhang H, Qi L, Du Y, et al. Patient-derived orthotopic xenograft (PDOX) mouse models of primary and recurrent meningioma. Cancers (Basel). 2020 Jun 5;12(6):1478. doi: 10.3390/cancers12061478
   PubMed Web of Science ®Google Scholar
• Chamberlain MC, Glantz MJ. Interferon-alpha for recurrent World Health Organization grade 1 intracranial meningiomas. Cancer. 2008 Oct 15;113(8):2146–2151. doi: 10.1002/cncr.23803
   PubMed Web of Science ®Google Scholar
• Brastianos PK, Kim AE, Giobbie-Hurder A, et al. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022 Mar 14;13(1):1325. doi: 10.1038/s41467-022-29052-7
   PubMed Web of Science ®Google Scholar
• Bi WL, Nayak L, Meredith DM, et al. Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. Neuro Oncol. 2022 Jan 5;24(1):101–113. doi: 10.1093/neuonc/noab118
   PubMed Web of Science ®Google Scholar